Experience of using the indacaterol from the position of cardiovascular safety
Abstract
Clinical efficacy of inhalation therapy by Onbrez®Breezhaler® and examination of the effect on the leading clinical symptoms, quality of life (COPD Assessment Test), lung function, heart rate, QTc interval and the potassium level in blood in hospital patients with COPD were under study. Based on the found evidence we can conclude that once daily administration of indacaterol at a dose of 150 mcg is an effective treatment for patients with COPD. It provides significant bronchodilation, reduces clinical manifestations, improves the quality of life of patients and has a favorable cardiovascular safety profile.
About the Authors
A. V. Melnik
ГБУЗ НСО «ГКБ №25»
Russian Federation
Russian Federation
N. I. Logvinenko
Новосибирский ГМУ МЗ РФ
Russian Federation
Russian Federation
S. V. Astrakov
НГМУ МЗ РФ; ГКБ № 25
Russian Federation
Russian Federation
References
1. Features of management of patients with chronic obstructive pulmonary disease in combination with cardiovascular diseases: methodical recommendations for doctors / E.D. Bazdyrev [et al.]. – Kemerovo, 2012. – 55 p.
2. Features of cardiac pathology in patients with bronchial asthma and COPD / E.V. Zaikina, A.A. Nizov [et al.] // Proceedings of Congress. XXIII National Congress on Diseases of the Respiratory System. – 2013. – P. 21.
3. The nature of arrhythmias in diseases of the respiratory system / N.Sh. Zagiddulin, Yu.F. Safina, G.R. Khalimova, U.R. Farhutdinov // Proceedings of the Congress. XXII National Congress on Diseases of the Respiratory System. – 2012. – P. 240.
4. Shugushev H.Kh. Supraventricular arrhythmias and high-resolution ECG in patients with chronic obstructive pulmonary disease on the background of bronchodilator therapy / X.H. Shugushev, M.V. Gurizheva, V.M. Vasilenko // Russian Cardiology Journal (Rus.). – 2010. – №6 (86). – P.40-44.
5. Shugushev H.Kh. Influence of bronchodilators on the heart rate variability in patients with chronic obstructive pulmonary disease / H.H. Shugushev, M.V. Gurizheva, V.M. Vasilenko // Rational Pharmacotherapy in Cardiology. 2007. № 4. – P. 51-54.
6. Atsou K. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review / K. Atsou, C. Chouaid, G. Hejblum// BMC Medicine. – 2011. – Vol. 9. – Р.7.
7. Bronchodilatator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study / M. Wilchesky, P. Ernst, J.M. Brophy, R.W. Platt, S.Suissa // Chest. – 2012. – №142(2). – P. 298–304.
8. Efficacy and safety of indacaterol 150 mg once-daily in COPD: a double-blind, randomised, 12-week study/ G. Feldman, T. Siler, N. Prasad [et al.] // BMC Pulm Med 2010; 10: 11.
9. Gulsvik A. Cardiac arrhythmias in patients with serious pulmonarydiseases /A. Gulsvik, V. Hansteen, E. Sivertssen // Scand J Respir Dis. 1978. – Vol. 59. – Р.154–159.
10. INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD/ D.E. O’Donnell, R. Casaburi, W. Vincken [et al.] // Respir Med 2011; 105 (7): 1030–6.
11. INHANCE Study Investigators.Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium/ J.F. Donohue, C. Fogarty, J. Lötvall [et al.] // Am J Respir Crit Care Med 2010; 182 (2): 155–62.
12. INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-mg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison/O. Kornmann, R. Dahl, S. Centanni [et al.] //Eur. Respir J 2011; 37 (2): 273–9.
13. On behalf of the INVOLVE Study Investigators. Efficacy of a new once-daily, long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD/R. Dahl, K.F. Chung, R. Buhl [et al.] // Thorax 2010; 65: 473–9.
14. Pauwels R.A. Burden and clinical features of chronic obstructive pulmonary disease (COPD) / R.A. Pauwels, K.F. Rabe // Lancet 2004; 364: 613–20.
15. Pulmonary function is a long_term predictor of mortality in the general population: 29-year follow_up of the Buffalo Health Study /H.J. Schunemann, J. Dorn, B.J. Grant [et al.] // Chest. – 2000. – Vol. 118. – P. 656-664.
16. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study / P. Buch, J. Friberg, H. Scharling [et al.]. – 2003. – Vol. 21 (6). – P. 1012-1016.
17. Rennard S.I. Bronchodilator sin chronic obstructive pulmonary disease. In: Management of chronic obstructive pulmonary disease. Ed. N.M.Siafakas. Eur. Respir .Monograph 2006; 11: 266-80
18. Respiratory symptoms and long-term cardiovascular mortality / A. Frostad, V. Soyseth, T. Haldorsen [et al.] // Respir Med 2007: 101: 2289–96.
19. Sin D.D. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature / D.D. Sin, L. Wu, S.F. Man// Chest. 2005. Vol. 127. Р. 1952–1959.
20. World Health Organisation Website. Chronic Obstructive Pulmonary Disease http://www.who.int/respiratory/copd.
21. World Health Organization. COPD predicted to be third leading cause of death in 2030. Available from: http://www.who.int/respiratory/copd/World_Health_Statistics_2008/en/. Accessed May 1, 2014.
Review
For citations:
Melnik A.V., Logvinenko N.I., Astrakov S.V. Experience of using the indacaterol from the position of cardiovascular safety. Yakut Medical Journal. 2017;(4):98-100.
Views:
5
Email this article 